English  |  正體中文  |  简体中文  |  Items with full text/Total items : 90069/105176 (86%)
Visitors : 6599754      Online Users : 608
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/112388


    Title: Phomaketide A Inhibits Lymphangiogenesis in Human Lymphatic Endothelial Cells
    Authors: Huai-Ching, T;Tai, Huai-Ching;Tzong-Huei, L;Lee, Tzong-Huei;湯智昕;Chih-Hsin;Tang;Chen, Lei-Po;Chen, Lei-Po;Ch, Wei-Cheng;Chen, Wei-Cheng;Ming-Shian, L;Lee, Ming-Shian;Chen, Pei-Chi;Chen, Pei-Chi;Li, Chih-Yang;Lin, Chih-Yang;Chi, Chih-Wen;Chi, Chih-Wen;Chen, Yu-Jen;Chen, Yu-Jen
    Contributors: 生物科技學系
    Date: 2019-04
    Issue Date: 2019-11-08 10:56:46 (UTC+8)
    Abstract: Lymphangiogenesis is an important biological process associated with cancer metastasis. The development of new drugs that block lymphangiogenesis represents a promising therapeutic strategy. Marine fungus-derived compound phomaketide A, isolated from the fermented broth of Phoma sp. NTOU4195, has been reported to exhibit anti-angiogenic and anti-inflammatory effects. However, its anti-lymphangiogenic activity has not been clarified to date. In this study, we showed that phomaketide A inhibited cell growth, migration, and tube formation of lymphatic endothelial cells (LECs) without an evidence of cytotoxicity. Mechanistic investigations revealed that phomaketide A reduced LECs-induced lymphangiogenesis via vascular endothelial growth factor receptor-3 (VEGFR-3), protein kinase Cδ (PKCδ), and endothelial nitric oxide synthase (eNOS) signalings. Furthermore, human proteome array analysis indicated that phomaketide A significantly enhanced the protein levels of various protease inhibitors, including cystatin A, serpin B6, tissue factor pathway inhibitor (TFPI), and tissue inhibitor matrix metalloproteinase 1 (TIMP-1). Importantly, phomaketide A impeded tumor growth and lymphangiogenesis by decreasing the expression of LYVE-1, a specific marker for lymphatic vessels, in tumor xenograft animal model. These results suggest that phomaketide A may impair lymphangiogenesis by suppressing VEGFR-3, PKCδ, and eNOS signaling cascades, while simultaneously activating protease inhibitors in human LECs. We document for the first time that phomaketide A inhibits lymphangiogenesis both in vitro and in vivo, which suggests that this natural product could potentially treat cancer metastasis.
    Relation: Marine Drugs
    Appears in Collections:[生物科技學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML17View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback